Can a vaccine and immune drug keep myeloma away after transplant?

NCT ID NCT01067287

Completed Disease control Sponsor: Beth Israel Deaconess Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a drug called CT-011 (a PD-1 blocker) and a dendritic cell vaccine given after a stem cell transplant in 35 people with multiple myeloma. The goal was to see if this combination is safe and can boost the immune system to fight remaining cancer cells. Researchers measured immune response by looking at T cell activity, hoping to delay or prevent the disease from coming back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pidilizumab (CT-011) and dendritic cell fusion vaccine
What this could lead to: If successful, this combination could help prevent or delay multiple myeloma from coming back after a stem cell transplant.
What could go wrong: This is a small, early-phase trial with only 35 participants. The treatment may not work for everyone and could cause side effects like immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02115, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Rambam Medical Center

Haifa, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.